Trinity Biotech increases profits
Trinity Biotech results showed a 38% in increased revenue and a 40% increase in pre-tax profits.
Revenue in the quarter rose to $11.4m (€12.6m) compared to $8.3m (€9.2m) in the same period a year ago.
Gross profit amounted to $5.6m (€6.2m) representing a gross margin of 49%.
Research and development expenses were $1m (€1.1m) up from $0.7m (€775k) a year ago.
Trinity Biotech has significantly increased its investment in direct sales and marketing operations both in the USA and in Germany.
